- Zacks Small Cap Research•last month
On December 19, 2016, MediciNova, Inc. (MNOV) announced that the Data and Safety Monitoring Board (DSMB) for the ongoing Phase 2b clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (MS) reviewed the results of the interim efficacy analysis and recommended to the National Institute of Neurological Diseases and Stroke (NINDS) that the trial should continue as planned, to which the NINDS has agreed. Thus, the fact that the DSMB recommended that the trial continue as planned is indicative that there is at least a positive trend in the direction of efficacy for MN-166. If there was no trend in favor of MN-166, the trial would have been stopped for futility.
- GlobeNewswire•last monthMediciNova Announces European Commission Grants Orphan Medicinal Product Designation for MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis
LA JOLLA, Calif., Dec. 20, 2016-- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, today announced that the European Commission ...
- GlobeNewswire•last monthMediciNova Announces Phase 2b Trial of MN-166 (ibudilast) in Progressive MS will Continue as Planned Following DSMB Review of Interim Efficacy Analysis
LA JOLLA, Calif., Dec. 19, 2016-- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, today announced that the external Data ...
MNOV : Summary for MediciNova, Inc. - Yahoo Finance
MediciNova, Inc. (MNOV)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||3.14 x 100|
|Ask||15.00 x 500|
|Day's Range||5.87 - 5.99|
|52 Week Range||3.76 - 10.16|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-15.41|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|